Therapeutic outcomes of PD-1 blockade-related regimens versus docetaxel in previously immunotherapy-treated advanced non-small cell lung cancer: a retrospective, exploratory study
Ting-Ting Huang, Xin-Ying Wang, Qin Li, Peng-Fei Song · 2026
Read Therapeutic outcomes of PD-1 blockade-related regimens versus docetaxel in previously immunotherapy-treated advanced non-small cell lung cancer: a retrospective, exploratory study by Ting-Ting Huang, Xin-Ying Wang, Qin Li, Peng-Fei Song (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13556055.txt.
Description
Ting-Ting Huang and three colleagues compared in 2026 two ways to treat advanced lung cancer after a first round of immunotherapy stops working. Their retrospective study covered patients treated between 2019 and 2025 whose disease had progressed on PD-1 or PD-L1 blocking drugs. One group received further PD-1 based combinations, with chemotherapy or a blood-vessel targeting drug, while the other received the standard chemotherapy drug docetaxel alone.
Response rates were modest in both groups, yet disease control was markedly better with the combination approach. Patients on PD-1 based regimens went longer before their cancer grew and lived longer overall, with median survival near seventeen months against about nine and a half on docetaxel. Side effects were compared as well. The authors frame the work as exploratory, since treatment was not assigned at random.
Catalog record
| CREATOR | Ting-Ting Huang, Xin-Ying Wang, Qin Li, Peng-Fei Song |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67422 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |